Sheldon Sloan, M.D., M. Bioethics, serves as the Chief Medical Officer at Spyre Therapeutics Inc., a biotechnology company focused on developing novel therapies for patients with inflammatory bowel disease (IBD). Dr. Sloan brings a wealth of experience to his role, having spent over two decades in the biopharmaceutical industry, where he has spearheaded numerous clinical development programs and regulatory strategies. His expertise spans across various therapeutic areas, including gastroenterology, immunology, and oncology, making him a pivotal figure in advancing Spyre's mission to address unmet medical needs in IBD. Prior to joining Spyre Therapeutics, Dr. Sloan held several key leadership positions at major pharmaceutical companies. Notably, he served as the Senior Vice President and Head of Global Development at Celgene Corporation, where he played a critical role in the development and approval of several blockbuster drugs. His strategic vision and deep understanding of clinical trial design and execution have been instrumental in bringing innovative treatments to market. Dr. Sloan's commitment to ethical medical practice is further evidenced by his Master's degree in Bioethics from the University of Pennsylvania, which complements his medical degree from the same institution. At Spyre Therapeutics, Dr. Sloan leads the clinical development team, overseeing the design and implementation of clinical trials aimed at evaluating the safety and efficacy of Spyre's pipeline candidates. His leadership is crucial in navigating the complex landscape of drug development, ensuring that Spyre's therapies meet the highest standards of scientific rigor and patient safety. Under his guidance, Spyre is poised to make significant strides in the field of gastroenterology, offering new hope to patients suffering from debilitating inflammatory bowel diseases.